Danaher Corporation Stock News

CNBC's Jim Cramer delivers his daily Mad Dash.

Danaher (DHR) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.76 per share a year ago.

Danaher Corp on Tuesday cut its annual sales growth forecast for a second straight quarter, signaling that funding crunch in the drug development market was weighing on its biotechnology business.

Danaher is an industry-leading serial acquirer with an iconic business system. After a boom in Danaher's sales during the pandemic, demand is now slowing as customers are facing inventory build-up and

Lower demand for COVID-19 testing, vaccine and therapeutics is expected to have hurt Danaher's (DHR) Q2 performance. Rising cost of sales might have hurt the bottom line.

Looking for undervalued blue-chip stocks to buy? This is a great time to be doing so.

Lower demand for COVID-19 testing, vaccine and therapeutics within the Biotechnology and Diagnostics segments weigh on Danaher (DHR).

Despite a great history of beating the number, this stock is a Zacks Rank #5 (Strong Sell) as earnings estimates have fallen.

WASHINGTON , June 20, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2023 on Tuesday, July 25, 2023

This year, so far, dividend investors are dealing with underperformance as the market has shifted from value to growth stocks. This is amplified by economic growth fears. While underperformance isn't

Thanks to its business model, Danaher has managed to reach operational excellence. Solid tailwinds will back up the company to continue its compounding path.

Earnings season has been better than feared, and we highlight two firms offering differing views on the state of the economy. There's also one falling Pharma company that (once again) delayed its Q3 r

Danaher Corporation (NYSE:DHR ) Bank of America Securities 2023 Healthcare Conference May 10, 2023 1:00 PM ET Company Participants Mike Ryskin - Analyst, Bank of America Life Science Tools and Diagnos

Warren Buffett held court again at Berkshire Hathaway's shareholder meeting. But his company could learn from some other S&P 500 companies.

It's been a good year for Bill Gates. According to the Bloomberg Billionaires Index , the Microsoft (NASDAQ: MSFT ) co-founder's net worth is up $15.5 billion to $125 billion.